The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1342
Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved pralatrexate (Folotyn – Allos), an intravenous (IV) antifolate, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the first drug approved by the FDA specifically for this indication.

MECHANISM OF ACTION — Pralatrexate is structurally related to methotrexate, but has a stronger affinity for dihydrofolate reductase. Inhibition of dihydrofolate reductase leads to cell death.

PERIPHERAL T-CELL LYMPHOMA — PTCLs account for 10-15% of newly diagnosed cases of non- Hodgkin’s lymphoma (NHL) in North America.1 The most common subtypes are PTCL not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma, which has the best prognosis of the three. T-cell lymphomas are generally more aggressive than their B-cell counterparts; PTCL-NOS has a median overall survival of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
Article code: 1342c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian